Finance Watch: Olema IPO Raises $209m To Advance OPI-1250 For Breast Cancer
Former AstraZeneca CMO Sean Bohen Helms The Phase I Firm
Olema launched this year’s 75th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
